A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 666-670

  Carter, Jori S ^a   Downs Jr , Levi S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Advanced epithelial ovarian carcinoma; Lenalidomide; Neutropenia; Safety; Topotecan

Indexed keywords

IMID; LENALIDOMIDE; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPITHELIUM TUMOR; FATIGUE; FEMALE; HUMAN; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PRURITUS; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; WOMEN'S HEALTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEUTROPENIA; OVARIAN NEOPLASMS; THALIDOMIDE; TOPOTECAN;

EID: 84855194634     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0243-1     Document Type: Article

References (21)

1. American Cancer Society (2010) Cancer facts and figures. Available via ACS http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc- 024113.pdf. Accessed August 2010
2. MA Bookman MP McGuire III D Kilpatrick, et al. 1996 Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group J Clin Oncol 14 1895 1902 8656258 1:CAS:528:DyaK28XjslOrsrc%3D (Pubitemid 26185464)
3. LS Downs PL Judson PA Argenta, et al. 2008 A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma Cancer (Phila) 112 331 339 10.1002/cncr.23164 1:CAS:528:DC%2BD1cXhs12gtrs%3D
4. Tohnya TM, Gulley J, Arlene P et al (2006) Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. J Clin Oncol 24(18 suppl):13038 (abstract)
5. SL Sanborn MM Cooney A Dowlati, et al. 2008 Phase I trial of docetaxel and thalidomide: a regimen based on metronomic principles Invest New Drugs 26 355 362 18470481 10.1007/s10637-008-9137-0 1:CAS:528:DC%2BD1cXnsVKiu7o%3D
6. EM Swisher DG Mutch JS Rader, et al. 1997 Topotecan in platinum- and paclitaxel-resistant ovarian cancer Gynecol Oncol 66 480 486 9299264 10.1006/gyno.1997.4787 1:STN:280:DyaK2svks1ejsw%3D%3D (Pubitemid 27388142)
7. Aravantinos G, Zafiropoulos A, Bafaloukos D et al (1998) Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy, Amsterdam: 67
8. WW Li M Hutnik G Gehr, et al. 2008 Antiangiogenesis in haematological malignancies Br J Haematol 143 622 631 19036013 10.1111/j.1365-2141.2008.07372.x
9. K Dredge R Horsfall SP Robinson, et al. 2005 Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res 69 56 63 15797261 10.1016/j.mvr.2005.01.002 1:CAS:528:DC%2BD2MXis1Gqtrc%3D (Pubitemid 40410468)
10. G Aue N Njuguna X Tian, et al. 2009 Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia Haematologica 94 1266 1273 19734418 10.3324/haematol.2009.005835 1:CAS:528:DC%2BD1MXhtlanurrN
11. LG Corral PA Haslett GW Muller, et al. 1999 Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 380 386 10384139 1:CAS:528:DyaK1MXkt1SisLw%3D (Pubitemid 29295864)
12. PH Schafer AK Gandhi MA Loveland, et al. 2003 Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs J Pharmacol Exp Ther 305 1222 1232 12649301 10.1124/jpet.102.048496 1:CAS:528:DC%2BD3sXkt1SntL4%3D (Pubitemid 36618002)
13. FE Davies N Raje T Hideshima, et al. 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216 11418482 10.1182/blood.V98.1.210 1:CAS:528:DC%2BD3MXkvFSlsrk%3D
14. T Hideshima D Chauhan Y Shima, et al. 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950 11049970 1:CAS:528:DC%2BD3cXnslGnsbw%3D
15. R Knight 2005 IMiDs: a novel class of immunomodulators Semin Oncol 32 suppl 5 S24 S30 16085014 10.1053/j.seminoncol.2005.06.018 1:CAS:528: DC%2BD2MXhtVWjt7%2FO
16. MA Dimopoulos E Terpos 2010 Lenalidomide: an update on evidence from clinical trials Blood Rev 24 suppl 1 S21 S26 21126633 10.1016/S0268-960X(10) 70005-9
17. D Zhu LG Corral YW Fleming, et al. 2008 Immunomodultory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation Cancer Immunol Immunother 57 1849 1859 18392823 10.1007/s00262-008-0512-7 1:CAS:528:DC%2BD1cXhtFCgu7jM
18. SM Temkin SD Yamada GF Fleming, et al. 2010 A phase I study of temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies Gynecol Oncol 117 473 476 20347480 10.1016/j.ygyno. 2010.02.022 1:CAS:528:DC%2BC3cXmtFajsbY%3D
19. F Gay SR Hayman MQ Lacy, et al. 2010 Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients Blood 115 1343 1350 20008302 10.1182/blood-2009-08-239046 1:CAS:528:DC%2BC3cXjtVWruro%3D
20. P Richardson S Jagannath M Hussein, et al. 2009 Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma Blood 114 772 778 19471019 10.1182/blood-2008-12-196238 1:CAS:528:DC%2BD1MXpsVCqurc%3D
21. AN Gordon JT Fleagle D Guthrie, et al. 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322 11454878 1:CAS:528: DC%2BD3MXlvVamsr8%3D (Pubitemid 32642183)